Beyond Nilotinib: A next-generation c-Abl inhibitor from Inhibikase Therapeutics (IkT-148009) has reached clinical-trial stage (Phase 1b)

[jeffreyn]

"The failure of Nilotinib to provide a clinically meaningful benefit in PD patients in two double-blind studies is discouraging, but may be explained by the fact that nilotinib does not accumulate in the brain at concentrations sufficient to inhibit c-Abl."

movementdisorders.onlinelib...

"... we anticipate completing this study and advancing into a Phase 2a study in 2022 ..."

parkinsonsnewstoday.com/202...

Good news once again, but, assuming this and future phases are successful, it will still be several years before any resulting drug becomes available.

[Hidden]

healthunlocked.com/cure-par...

healthunlocked.com/cure-par...

[jeffreyn in reply to Hidden]

Hi nedim,

Thanks for the links. I'd seen your first link before, but I missed your second one somehow.

Jeff

[MarionP]

Is this the one recently approved in US but under cloud of insufficient evidence, approved despite the expert panel expressly declining to recommend for approval, and at extreme cost?

[jeffreyn in reply to MarionP]

No. I think you might be thinking of the Alzheimer's drug Aducanumab.

alz.org/alzheimers-dementia...

[FMundo]

Suggest you read my post on nilotinib today

[Isthistheone in reply to FMundo]

Hi Frank welcome to the show. How's AZ? I never will find fault with opinions, NOT GOING FORWARD WITH GU PLAN IS A MISTAKE!! GIVE EM A LASHING!! TAKE CARE AND MERRY CHRISTMAS!!

[Isthistheone]

Jeff, this is exactly my point. While we wait for the Perfect Plan how many years tick by. Take GEORGETOWN UNIVERSITY Good Plan and learn from it. "If they can penicillin from moldy bread they can make something out of you."